Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : LLY crawled time : 21:00 save search
CKD Leaders Network Publishes New Thought Piece in Journal of Clinical Medicine
Published: 2024-03-21 (Crawled : 21:00) - prnewswire.com
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: -0.03%
H: 0.91%
C: 0.08%
network leaders
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
Published: 2024-02-28 (Crawled : 21:00) - globenewswire.com
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: -0.6%
H: 0.45%
C: 0.08%
MRUS | $41.05 1.84% 1.71% 410K
|
Health Technology
|
| O: 2.3%
H: 0.58%
C: -2.69%
INCY | $52.72 -0.94% -0.91% 2.1M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: -3.07%
business year update financial results
Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer
Published: 2024-02-21 (Crawled : 21:00) - biospace.com/
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: -2.33%
H: 1.55%
C: 1.06%
JAZZ | News | $107.1 -1.65% -1.63% 590K
|
Health Technology
|
| O: -0.12%
H: 1.79%
C: 1.75%
pharmaceuticals financial
BioMarin Announces Governance Enhancements and Value Creation Initiatives
Published: 2023-12-20 (Crawled : 21:00) - prnewswire.com
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: 0.21%
H: 0.63%
C: 0.1%
XRAY | News A | $30.36 -1.4% -1.42% 1.4M
|
Health Technology
|
| O: 1.15%
H: 2.32%
C: 2.27%
BMRN | News S | $90.47 -0.44% -0.43% 1.3M
|
Health Technology
|
| O: 1.44%
H: 2.43%
C: 1.24%
Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement
Published: 2023-12-01 (Crawled : 21:00) - globenewswire.com
VERV | $6.74 -5.6% -5.93% 890K
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
| Email alert
Add to watchlist
offering therapeutics
Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
Published: 2023-11-28 (Crawled : 21:00) - globenewswire.com
VERV | $6.74 -5.6% -5.93% 890K
|
Professional, Scientific, and T...
|
| O: -11.15%
H: 13.21%
C: 5.66%
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
offering therapeutics
Alexandria Real Estate Equities, Inc. Announces Exclusive Partnership With Lilly to Expand Lilly Gateway Labs to San Diego
Published: 2023-11-28 (Crawled : 21:00) - biospace.com/
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: 0.05%
H: 0.0%
C: 0.0%
ARE A | $116.45 -0.46% 0.01% 450K
|
Finance
|
| O: -0.19%
H: 3.05%
C: 2.77%
partnership
Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights
Published: 2023-11-08 (Crawled : 21:00) - prnewswire.com
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: -0.71%
H: 0.14%
C: -3.81%
RNA | $23.55 -1.51% -1.51% 720K
|
Health Technology
|
| O: 3.51%
H: 9.47%
C: -2.32%
financial results
FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems
Published: 2023-11-08 (Crawled : 21:00) - biospace.com/
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: 1.29%
H: 3.0%
C: 1.89%
fda obesity treatment medical tirzepatide
Primary Sclerosing Cholangitis Market to Grow at a Tremendous CAGR of 17.2% During the Study Period (2019-2032) | DelveInsight
Published: 2023-10-31 (Crawled : 21:00) - prnewswire.com
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
|
| O: 0.94%
H: 2.55%
C: 2.55%
ALPMY | News | $9.46 1.29% -1.11% 500K
|
Manufacturing
|
| O: -4.18%
H: 0.49%
C: -0.02%
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: -2.76%
H: 0.0%
C: 0.0%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
PLRX | $12.86 -3.02% -3.11% 200K
|
Health Technology
|
| O: -0.2%
H: 3.45%
C: 1.37%
CALT | $18.74 5.29% 5.32% 6.8K
|
Health Technology
|
| O: -2.27%
H: 2.01%
C: 0.44%
study market
High-grade Glioma Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Companies to Watch Out - BioMimetix, Bayer, MedImmune, DNAtrix, Chimerix, Bristol-Myers Squibb, Laminar, Immunomic, Inovio
Published: 2023-10-25 (Crawled : 21:00) - prnewswire.com
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: -1.68%
H: 0.0%
C: 0.0%
companies growth market
Cholangiocarcinoma Treatment Drugs Market to Rise by 2032 | Key Analysis by DelveInsight
Published: 2023-10-18 (Crawled : 21:00) - prnewswire.com
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: -1.17%
H: 0.0%
C: 0.0%
XNCR | $19.07 0.79% 0.84% 460K
|
Health Technology
|
| O: 0.0%
H: 0.48%
C: -1.98%
RLAY | $6.21 -7.86% -8.36% 1.9M
|
Health Technology
|
| O: 0.28%
H: 0.14%
C: -4.37%
treatment market
Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period (2019-2032), Assesses DelveInsight | Leading Companies - Amgen, Novartis, AbbVie, BMS, Clovis Oncology, Cardiff Oncology, Roche, Daiichi Sankyo
Published: 2023-10-04 (Crawled : 21:00) - prnewswire.com
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: 1.72%
H: 0.0%
C: 0.0%
RVMD S | $36.82 1.57% 1.55% 920K
|
Health Technology
|
| O: -0.58%
H: 4.83%
C: 4.38%
IOVA M | $11.8 -1.01% -1.02% 3.1M
|
Health Technology
|
| O: 0.24%
H: 3.66%
C: 1.95%
BNTX | $86.4 0.07% 0.09% 1.2M
|
Health Technology
|
| O: -0.44%
H: 1.52%
C: 0.08%
AXSM | $69.71 1.31% 1.26% 340K
|
Health Technology
|
| O: -0.43%
H: 4.97%
C: 4.71%
lung companies cancer study market
Narcolepsy Market Analysis, Market Size, Epidemiology, and Competitive Analysis of Leading Companies Including Takeda, Suven Life Sciences Limited, Axsome Therapeutics, Inc., Avadel, and Others by DelveInsight
Published: 2023-10-03 (Crawled : 21:00) - prnewswire.com
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: -2.39%
H: 0.0%
C: 0.0%
AXSM | $69.71 1.31% 1.26% 340K
|
Health Technology
|
| O: -0.66%
H: 2.5%
C: 1.89%
ACAD | News | $17.19 0.64% 0.7% 690K
|
Health Technology
|
| O: -0.82%
H: 5.05%
C: 4.42%
companies life narcolepsy sciences market
Neuroblastoma Market to Grow at a Substantial Growth Rate During the Forecast Period (2023-2032), Examines DelveInsight | Key Companies to Watch - Y-mAbs, Exelixis, Clarity, Eli Lilly, Innervate Radiopharmaceuticals, Adaptimmune
Published: 2023-09-28 (Crawled : 21:00) - prnewswire.com
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: 1.64%
H: 0.04%
C: -0.57%
CRIS | $15.95 4.45% 2.99% 37K
|
Health Technology
|
| O: -21.05%
H: 23.86%
C: 9.83%
CLRB | $3.21 -3.02% -3.44% 850K
|
Health Technology
|
| O: 0.79%
H: 8.2%
C: 3.13%
companies growth market
Chronic Lower Back Pain Market to Showcase Tremendous Growth by 2032, Predicts DelveInsight | Key Companies to Look Out - Eli Lilly, Camurus, Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG
Published: 2023-09-21 (Crawled : 21:00) - prnewswire.com
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: -2.93%
H: 1.22%
C: 0.32%
MESO | $5.01 6.82% 6.76% 490K
|
Health Technology
|
| O: 4.35%
H: 0.0%
C: -6.06%
companies back growth market
Intrahepatic Cholangiocarcinoma Market to Grow Rapidly During the Study Period (2019-2032), Examines DelveInsight | Key Players - Virogin Biotech, Syndax, Delcath Systems, AstraZeneca, Amgen, Jazz, BeiGene
Published: 2023-09-20 (Crawled : 21:00) - prnewswire.com
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: -1.47%
H: 0.0%
C: 0.0%
XNCR | $19.07 0.79% 0.84% 460K
|
Health Technology
|
| O: -0.39%
H: 1.03%
C: -0.59%
RLAY | $6.21 -7.86% -8.36% 1.9M
|
Health Technology
|
| O: -2.04%
H: 0.87%
C: -0.46%
INCY | $52.72 -0.94% -0.91% 2.1M
|
Health Technology
|
| O: -0.22%
H: 0.25%
C: -2.37%
BGNE S | $131.86 -1.63% -1.64% 180K
|
Health Technology
|
| O: -2.14%
H: 0.25%
C: -0.49%
study market
Head and Neck Squamous Cell Carcinoma Market to Witness Upsurge in Growth by 2032, Assesses DelveInsight | Key Companies in the Market - Pfizer, Merck, Eisai, AstraZeneca, Innate, Roche, GlaxoSmithKline, BeiGene, IO Biotech, Incyte
Published: 2023-09-18 (Crawled : 21:00) - prnewswire.com
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
|
| O: -0.62%
H: 0.0%
C: -1.16%
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: 0.06%
H: 1.19%
C: 0.58%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: -0.09%
H: 1.16%
C: 1.16%
MRUS | $41.05 1.84% 1.71% 410K
|
Health Technology
|
| O: -0.16%
H: 2.46%
C: 0.56%
KURA | $17.99 -3.23% -3.28% 660K
|
Health Technology
|
| O: -0.1%
H: 2.4%
C: 0.52%
IOVA M | $11.8 -1.01% -1.02% 3.1M
|
Health Technology
|
| O: -0.51%
H: 1.5%
C: -7.97%
INCY | $52.72 -0.94% -0.91% 2.1M
|
Health Technology
|
| O: 0.03%
H: 2.18%
C: 1.8%
FUSN | $21.24 -0.09% -0.09% 350K
|
Health Technology
|
| O: 0.0%
H: 0.41%
C: -2.26%
CALT | $18.74 5.29% 5.32% 6.8K
|
Health Technology
|
| O: -6.2%
H: 4.2%
C: 0.0%
BNTX | $86.4 0.07% 0.09% 1.2M
|
Health Technology
|
| O: -0.01%
H: 1.99%
C: 1.28%
companies cell growth market
Triple-Negative Breast Cancer Market to Accelerate Substantially During the Forecast Period (2023-2032), Examines DelveInsight | Key Companies to Watch - Roche, AbbVie, AstraZeneca, BeiGene, GlaxoSmithKline, Genentech, Eli Lilly, Novartis
Published: 2023-09-06 (Crawled : 21:00) - prnewswire.com
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: 0.76%
H: 2.15%
C: 1.6%
RCUS 4 | $14.84 -6.49% -0.67% 790K
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: -4.96%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: 0.0%
IOVA M | $11.8 -1.01% -1.02% 3.1M
|
Health Technology
|
| O: -1.5%
H: 0.83%
C: -1.69%
IMMP | News | $2.26 -0.22% 200K
|
Health Technology
|
| O: 0.53%
H: 0.53%
C: 0.53%
GTHX | News | $4.28 4.9% 4.67% 690K
|
Health Technology
|
| O: -0.6%
H: 1.2%
C: 0.0%
BNTX | $86.4 0.07% 0.09% 1.2M
|
Health Technology
|
| O: -1.16%
H: 1.14%
C: 0.89%
companies breast cancer novartis market
Polycythemia Vera Market Grow Rapidly at a CAGR of 14% During the Study Period (2019-2032) | DelveInsight
Published: 2023-09-05 (Crawled : 21:00) - prnewswire.com
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: 0.51%
H: 0.1%
C: -0.19%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: -0.83%
H: 0.19%
C: -0.09%
INCY | $52.72 -0.94% -0.91% 2.1M
|
Health Technology
|
| O: -0.08%
H: 0.44%
C: -0.06%
study market
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
INVO | $1.82 139.47% 56.82% 220M
|
Health Technology
SINT | $0.0373 62.88% 37.26% 460M
|
Health Technology
WISA 4 | $9.25 51.64% 34.27% 64M
|
Electronic Technology
EDBL | News | $6.66 46.37% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 600K
|
Manufacturing
TCON | $2.29 33.92% 26.61% 1.8M
|
Health Technology
TIRX | $0.4848 7.49% 24.58% 5.9M
|
SRFM 4 | $0.3859 -12.3% 23.84% 660K
|
n/a
KZIA | $0.3442 18.28% 23.42% 290K
|
Health Technology
CTM | $0.2201 -2.31% 22.67% 48K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.